Literature DB >> 2475433

Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.

J E Kay1, C R Benzie, M R Goodier, C J Wick, S E Doe.   

Abstract

Nanamolar concentrations of the immunosuppressive drug FK-506 inhibit the induction of T-lymphocyte proliferation by the lectins concanavalin A (Con A) and phytohaemagglutinin (PHA). Activation by Con A is more sensitive to inhibition than the response to PHA. FK-506 inhibits an early Ca2+-dependent step in the activation process, and its effects are not reversible by the addition of recombinant interleukin-2 (IL-2) or lymphokine-rich culture supernatant. While the effects of suboptimal concentrations of FK-506 and cyclosporin A (CsA) are additive, FK-506 does not enhance the effects of optimal concentrations of CsA. Both drugs also have similar effects on the expression of specific mRNA in Con A-activated lymphocytes. A brief preincubation of unstimulated cells with FK-506 irreversibly inhibits their subsequent responsiveness to Con A. The mechanism of action of FK-506 thus resembles that of CsA, except that it is effective at two to three orders of magnitude lower concentrations and its effects are much less readily reversible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475433      PMCID: PMC1385316     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  The control of protein synthesis during the stimulation of lymphocytes by phytohaemagglutinin. III. Poly(U) translation and the rate of polypeptide chain elongation.

Authors:  J E Kay; T Ahern; V J Lindsay; J Sampson
Journal:  Biochim Biophys Acta       Date:  1975-01-20

2.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

3.  Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

Authors:  S Sawada; G Suzuki; Y Kawase; F Takaku
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  Immunosuppressive effect of FK506 on experimental allergic encephalomyelitis in rats.

Authors:  N Inamura; M Hashimoto; K Nakahara; Y Nakajima; M Nishio; H Aoki; I Yamaguchi; M Kohsaka
Journal:  Int J Immunopharmacol       Date:  1988

6.  Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506.

Authors:  J Woo; M Stephen; A W Thomson
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

7.  Cyclosporin as a probe for different modes of lymphocyte activation.

Authors:  G G Klaus
Journal:  Ann Inst Pasteur Immunol       Date:  1987 Jul-Aug

8.  The cyclosporin-A-sensitive event in lymphocyte activation.

Authors:  J E Kay
Journal:  Ann Inst Pasteur Immunol       Date:  1987 Jul-Aug

9.  Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes.

Authors:  N Kumagai; S H Benedict; G B Mills; E W Gelfand
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

10.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982

View more
  16 in total

1.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium.

Authors:  M L Jordan; S Hignet; J Wright; R A Hoffman; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.

Authors:  A Zeevi; M Woan; G Z Yao; R Venkataramanan; S Todo; T E Starzl; R J Duquesnoy
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Inhibition by FK506 of established lesions of collagen-induced arthritis in rats.

Authors:  C Arita; T Hotokebuchi; H Miyahara; K Arai; Y Sugioka; N Kaibara
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

5.  Evidence that calcineurin is rate-limiting for primary human lymphocyte activation.

Authors:  T D Batiuk; L Kung; P F Halloran
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

6.  The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.

Authors:  P S Randhawa; R Shapiro; M L Jordan; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1993-01       Impact factor: 6.394

7.  Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

Authors:  P Walliser; C R Benzie; J E Kay
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

8.  Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.

Authors:  Kazuhiko Haruta; Shigeyuki Mori; Naoto Tamura; Asako Sasaki; Masakazu Nagamine; Shin-ichi Yaguchi; Fumitaka Kamachi; Jumpei Enami; Shigeto Kobayashi; Takao Yamori; Yoshinari Takasaki
Journal:  Inflamm Res       Date:  2012-02-15       Impact factor: 4.575

9.  Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; C van Kooten; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

Review 10.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.